Pharma BD Deal Intelligence
AstraZeneca closes acquisition of Amolyt Pharma, expanding rare disease pipeline with eneboparatide for hypoparathyroidism
Eneboparatide met the primary endpoint of normalising serum calcium at 24 weeks in the Phase III CALYPSO trial (202 adults with chronic hypoparathyroidism).…
AstraZeneca strengthens rare disease portfolio with Amolyt Pharma acquisition valued at up to $1.05 billion including CVRs
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AstraZeneca acquired Amolyt Pharma for $1.05B for eneboparatide for hypoparathyroidism.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Amolyt Pharma (this deal) | 2024 | $1.1B | 73 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2024 deals · AstraZeneca PLC deals · Rare Disease deals